Dynavax Technologies Corp at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Hello, everyone, and thank you for joining the H. C. Wainwright Fourth Annual Hepatitis B Virus Virtual Conference. My name is Ed White, and I'm a senior analyst here at H. C. Wainwright covering Dynavax Technologies, ticker DVAX.
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing novel vaccines utilizing innovative adjuvant technology. HEPLISAV-B is the company's two-dose vaccine that is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 and older.
Now it is my pleasure to introduce Kelly MacDonald, CFO of Dynavax. Thanks for taking part in the conference, Kelly.
Thank you, Ed, and thank you all for joining us today. Before we begin, I'd like to recognize that the presentation contains forward-looking statements that have certain risks and uncertainties that are highlighted in our Risk Factors, in the Form 10-Q, as well as our other SEC
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |